On the heels of a stock surge that began when RNAi competitor Sirna Therapeutics Inc. received a hefty buyout offer from Merck & Co. Inc., Alnylam Pharmaceuticals Inc. is raising $101 million through the sale of common stock. (BioWorld Today) Read More